dc.contributor.author | GEDİKBAŞI, Asuman | |
dc.contributor.author | Kumbasar, Abdulbaki | |
dc.contributor.author | Hursitoglu, Mehmet | |
dc.contributor.author | Acarer, Didem | |
dc.contributor.author | Harmankaya, Ozlem | |
dc.contributor.author | OKUTURLAR, Yıldız | |
dc.contributor.author | Gunaldi, Meral | |
dc.contributor.author | Kocoglu, Hakan | |
dc.date.accessioned | 2021-03-02T22:55:28Z | |
dc.date.available | 2021-03-02T22:55:28Z | |
dc.identifier.citation | OKUTURLAR Y., Gunaldi M., Kocoglu H., Hursitoglu M., GEDİKBAŞI A., Acarer D., Harmankaya O., Kumbasar A., "Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer", JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, 2018 | |
dc.identifier.issn | 0973-1482 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_0f7fa1d8-4174-4607-aed6-e1bf454525b0 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/15959 | |
dc.identifier.uri | https://doi.org/10.4103/0973-1482.235355 | |
dc.description.abstract | Aim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC. | |
dc.language.iso | eng | |
dc.subject | Onkoloji | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | |
dc.contributor.department | Bakirkoy Dr. Sadi Konuk Research & Training Hospital , , | |
dc.identifier.volume | 14 | |
dc.contributor.firstauthorID | 2214745 | |